Vanguard Group
ZNTL icon

Vanguard Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Vanguard Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.86M Sell
2,855,590
-48,810
-2% -$71K ﹤0.01% 3351
2025
Q3 		$4.39M Buy
2,904,400
+19,768
+0.7% +$29.6K ﹤0.01% 3320
2025
Q2 		$3.35M Sell
2,884,632
-375,980
-12% -$496K ﹤0.01% 3351
2025
Q1 		$5.18M Sell
3,260,612
-10,628
-0.3% -$22.9K ﹤0.01% 3157
2024
Q4 		$9.91M Sell
3,271,240
-1,341,467
-29% -$4.4M ﹤0.01% 2967
2024
Q3 		$17M Sell
4,612,707
-1,042,050
-18% -$3.79M ﹤0.01% 2669
2024
Q2 		$23.1M Buy
5,654,757
+1,256,132
+29% +$14M ﹤0.01% 2500
2024
Q1 		$69.3M Sell
4,398,625
-951,833
-18% -$13.1M ﹤0.01% 2033
2023
Q4 		$81.1M Buy
5,350,458
+113,795
+2% +$1.66M ﹤0.01% 1965
2023
Q3 		$105M Buy
5,236,663
+307,490
+6% +$7.8M ﹤0.01% 1784
2023
Q2 		$139M Buy
4,929,173
+688,558
+16% +$16.5M ﹤0.01% 1669
2023
Q1 		$72.9M Buy
4,240,615
+80,466
+2% +$1.63M ﹤0.01% 1984
2022
Q4 		$83.8M Buy
4,160,149
+53,888
+1% +$1.16M ﹤0.01% 1901
2022
Q3 		$88.9M Sell
4,106,261
-386,074
-9% -$10.6M ﹤0.01% 1858
2022
Q2 		$126M Buy
4,492,335
+1,251,750
+39% +$33.2M ﹤0.01% 1681
2022
Q1 		$150M Buy
3,240,585
+53,599
+2% +$2.89M ﹤0.01% 1730
2021
Q4 		$268M Buy
3,186,986
+55,101
+2% +$4.26M 0.01% 1424
2021
Q3 		$209M Buy
3,131,885
+297,061
+10% +$17.1M 0.01% 1579
2021
Q2 		$151M Buy
2,834,824
+415,976
+17% +$22.3M ﹤0.01% 1783
2021
Q1 		$105M Buy
2,418,848
+72,711
+3% +$3.13M ﹤0.01% 1919
2020
Q4 		$122M Buy
2,346,137
+1,212,170
+107% +$54.7M ﹤0.01% 1735
2020
Q3 		$37.1M Buy
1,133,967
+307,025
+37% +$10.7M ﹤0.01% 2165
2020
Q2 		$39.7M Buy
+826,942
New +$31.7M ﹤0.01% 2118

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vanguard Group's ZNTL Position: Q4 2025 in Review

Vanguard Group reduced its Zentalis Pharmaceuticals (ZNTL) stake by 1.7% in Q4 2025, selling an estimated $71K and leaving 2,855,590 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3351.

Vanguard Group first reported a position in ZNTL in Q2 2020 and has held it in 23 quarters since. The position peaked at $268M in Q4 2021. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • Vanguard Group held 2,855,590 shares of Zentalis Pharmaceuticals worth $3.86M as of Q4 2025.
  • Vanguard Group sold 48,810 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $71K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3351 holding.
  • Vanguard Group first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Zentalis Pharmaceuticals position peaked at $268M in Q4 2021.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.